. home.aspx



Boehringer settles Humira lawsuit, joins biosimilar queue in US

May 15, 2019 / Phil Taylor

Boehringer Ingelheim was the last man standing among challengers to AbbVie’s patents on immunology blockbuster Humira but has joined the pack and settled its litigation. The German company has agreed to delay the introduction of its Humira (adalimumab) biosimilar Cyltezo until 2023, following the example of Amgen, Merck & Co/Samsung Bioepis, Mylan/Fujifilm and Novartis’ Sandoz unit. AbbVie now has breathing space in the US to try to reduce its over-reliance on Humira, which brought in almost $20 billion in sales last year to account for nearly two-thirds of its total turnover in the year. It says the settlement with Boehringer doesn’t involve any payments “of any form”, and that Boehringer will pay royalties to AbbVie for licensing its patents. Humira grew 7% in the US last year, mainly due to price increases, but the product felt the effects of biosimilar competition in the smaller European market, where sales operationally fell 23% after patent prote...